4-(2-fluorophenyl)-4-hydroxy-1-methylpiperidine | 72365-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(2-fluorophenyl)-4-hydroxy-1-methylpiperidine
• 英文别名: 4-(2-Fluorophenyl)-1-methylpiperidin-4-OL
• CAS: 72365-19-6
• 化学式: C₁₂H₁₆FNO
• 分子量: 209.264
• InChiKey: MUVGBRLYRTVCSM-UHFFFAOYSA-N

物化性质

• 熔点：
  127-129 °C(Solv: benzene (71-43-2); hexane (110-54-3))
• 沸点：
  325.5±42.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-fluorophenyl)-4-hydroxy-1-methylpiperidine 在 三氟化硼 、 dimsyl sodium 、 溶剂黄146 作用下， 以 二甲基亚砜 为溶剂， 反应 16.0h， 生成 1,3-dihydro-1'-methyl-3-phenylspiro[benzo(c)thiophene-1,4'-piperidine]
  参考文献：
  名称：

  Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants

  摘要：

  A series of 3-aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidine] derivatives was synthesized and evaluated pharmacologically for potential psychotropic activity. Potent antidepressant-like activity was noted throughout the series, as assessed by tetrabenazine (TBZ) ptosis prevention in mice and potentiation of 5-hydroxytryptophan (5-HTP) induced behavioral effects in rats. A possible therapeutic advantage of the title compounds appears to be the overall low anticholinergic potential in comparison with the classic tricyclic antidepressants. Several congeners with nuclear halogen substitution also exhibited CNS stimulant properties, as evidenced by their ability to induce a dopamine agonist-like stereotypy and to increase the spontaneous motor activity in mice.

  DOI：

  10.1021/jm00133a016
• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 邻溴氟苯 在 正丁基锂 作用下， 生成 4-(2-fluorophenyl)-4-hydroxy-1-methylpiperidine
  参考文献：
  名称：

  Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants

  摘要：

  A series of 3-aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidine] derivatives was synthesized and evaluated pharmacologically for potential psychotropic activity. Potent antidepressant-like activity was noted throughout the series, as assessed by tetrabenazine (TBZ) ptosis prevention in mice and potentiation of 5-hydroxytryptophan (5-HTP) induced behavioral effects in rats. A possible therapeutic advantage of the title compounds appears to be the overall low anticholinergic potential in comparison with the classic tricyclic antidepressants. Several congeners with nuclear halogen substitution also exhibited CNS stimulant properties, as evidenced by their ability to induce a dopamine agonist-like stereotypy and to increase the spontaneous motor activity in mice.

  DOI：

  10.1021/jm00133a016

文献信息

• UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF
  申请人：RAPT THERAPEUTICS, INC.

  公开号：US20210317134A1

  公开（公告）日：2021-10-14

  Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.

  本公开的内容包括化合物及其使用方法，用于调节USP7活性。
• 4-Pentafluorophenoxypiperidines
  申请人：Hoechst-Roussel Pharmaceuticals Incorporated

  公开号：US04914204A1

  公开（公告）日：1990-04-03

  4-Pentafluorophenoxypiperidines and methods for alleviating pain and treating depression, convulsions, and hypertension utilizing compounds or compositions thereof are disclosed.

  4-五氟苯氧哌啶和利用其化合物或组合物缓解疼痛、治疗抑郁症、癫痫和高血压的方法被披露。
• Antidepressive and tranquilizing substituted
  申请人：Hoechst-Roussel Pharmaceuticals, Inc.

  公开号：US04409229A1

  公开（公告）日：1983-10-11

  Novel substituted 1,3-dihydrospiro[benzo(c)thiophene]s and methods of preparing the same are described. These compounds are useful as antidepressants and tranquilizers and intermediates therefor.

  本发明描述了一种替代了1,3-二氢螺[苯并(c)噻吩]的新型化合物及其制备方法。这些化合物可用作抗抑郁和镇静药物，也可用作它们的中间体。
• Process for preparing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04524207A1

  公开（公告）日：1985-06-18

  Novel substituted 1,3-dihydrospiro[benzo(c)thiophene]s and methods of preparing the same are described. These compounds are useful as antidepressants and tranquilizers and intermediates therefor.

  本发明涉及代替1,3-二氢螺[苯并(c)噻吩]的新型化合物及其制备方法。这些化合物可用作抗抑郁剂和镇静剂，也可作为其中间体。
• Modulators of CB1 Receptors
  申请人：Cooper Martin

  公开号：US20100144701A1

  公开（公告）日：2010-06-10

  Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight: wherein A 1 is hydrogen, —COOH,or tetrazolyl; p and q are independently 0 or 1; A3 is phenyl or cycloalkyl, either of which is optionally substituted with R 4 and/or R 5 ; R 4 and R 5 are independently —R 9 , —CN, —F, —Cl, —Br, —OR 9 , —NR 7 R 8 , —NR 7 COR 6 , —NR 7 SO 2 R 6 , —COR 6 , —SR 9 , —SOR 9 , or —SO 2 R 6 ; R 6 is C 1 -C 4 alkyl, cycloalkyl, —CF 3 or —NR 7 R 8 ; R 7 and R 8 are independently hydrogen, C 1 -C 4 alkyl or cycloalkyl; R 9 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkoxy(C 1 -C 4 alkyl)-, cycloalkyl, or fully or partially fluorinated C 1 -C 4 alkyl; R 1 (i) a bond; (ii) a divalent radical of formula —(CH 2 ) a B 1 (CH 2 ) b wherein a and b are independently O, 1, 2 or 3 provided that a+b is 1, 2 or 3, and B 1 is —CO—, —O—, —S—, —SO—, —SO 2 —, —CH 2 —, —CHCH 3 —, —CHOH— or —NR 7 —; or (iii) a divalent radical selected from —C(R 10 )(R 11 )—*, —C(R 10 )(R 11 )—O—*, —C(R 10 )(R 11 )CH 2 —*, —C(R 10 )(R 11 )CH 2 —O—*, —CH 2 C(R 10 )(R 11 )—*, —CH 2 C(R 10 )(R 11 )—O—*, —CH 2 —O—C(R 10 )(R 11 )—* and —C(R 10 )(R 11 )—O—CH 2 —*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is as defined in the specification; R 10 is hydrogen and R 11 is (C 1 -C 3 )alkyl or —OH; or R 10 and R 11 are both (C 1 -C 3 )alkyl; or R 10 and R 11 taken together with the carbon atom to which they are attached form a (C 3 -C 5 )cycloalkyl ring.

  式(I)的化合物抑制CB1受体的正常信号活动，因此可用于治疗由CB1受体信号活动介导的疾病或症状，例如肥胖和超重的治疗，预防体重增加，直接或间接与肥胖和超重相关的疾病和症状的治疗：其中A1是氢，-COOH或四唑基；p和q独立地为0或1；A3是苯基或环烷基，其中任一可选地用R4和/或R5取代；R4和R5独立地为-R9，-CN，-F，-Cl，-Br，-OR9，-NR7R8，-NR7COR6，-NR7SO2R6，-COR6，-SR9，-SOR9或-SO2R6；R6是C1-C4烷基，环烷基，-CF3或-NR7R8；R7和R8独立地为氢，C1-C4烷基或环烷基；R9为氢，C1-C4烷基，C1-C4烷氧基，C1-C4烷氧基（C1-C4烷基）-，环烷基或完全或部分氟化的C1-C4烷基；R1(i)为键；（ii）为式-（CH2）aB1（CH2）b的二价基团，其中a和b独立地为O，1，2或3，前提是a+b为1，2或3，B1为-CO-，-O-，-S-，-SO-，-SO2-，-CH2-，-CHCH3-，-CHOH-或-NR7-；或（iii）为从-C（R10）（R11）- *，-C（R10）（R11）-O- *，-C（R10）（R11）CH2- *，-C（R10）（R11）CH2- O- *，-CH2C（R10）（R11）- *，-CH2C（R10）（R11）-O- *，-CH2-O-C（R10）（R11）- *和-C（R10）（R11）-O-CH2- *中选择的二价基团，其中由星号表示的键连接到吡唑环；Z如规范中所定义；R10为氢，R11为（C1-C3）烷基或-OH；或R10和R11均为（C1-C3）烷基；或R10和R11与它们连接的碳原子一起形成（C3-C5）环烷基环。